Percutaneous coronary intervention or coronary artery bypass graft surgery for left main coronary artery disease: A meta-analysis of randomized trials - 25/08/20
Abstract |
We aimed to investigate long-term (≥5 years) outcomes of percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) for left main coronary artery disease (LMCAD) using a meta-analysis from updated published randomized trials. Our data showed that the risk of all-cause death as well as cardiovascular death, myocardial infarction, and stroke was similar between PCI and CABG, whereas PCI had significantly higher rates of repeat revascularization compared to CABG. Decisions for PCI versus CABG for LMCAD should be based on weighing the upfront morbidity and mortality risk of CABG with late risk of repeat revascularization with PCI and taking into consideration patient preference.
Le texte complet de cet article est disponible en PDF.Plan
☆ | Disclosure: Dr Bangalore is an advisory board member for Abbott Vascular, Biotronik, Amgen, Pfizer, and Reata. Dr Cohen is a consultant for AstraZeneca, Medtronic, Merit Medical, Terumo Medical, and Abiomed. The remaining authors have nothing to disclose. |
☆☆ | Kim A. Eagle, MD, served as guest editor for this article. |
Vol 227
P. 9-10 - septembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?